Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 2085-2088

  Chen, Huang Yao ^a   Yu, Ming Chih ^b   Huang, Wei Lun ^a   Wu, Mei Hua ^a   Chang, Yung Lin ^a   Che, Chien Rai ^a   Jou, Ruwen ^a,c  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RIFABUTIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DNA PROBE; DRUG POTENCY; FEASIBILITY STUDY; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENOTYPING TECHNIQUE; LABORATORY TEST; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE;

ANTITUBERCULAR AGENTS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84862103659     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00652-12     Document Type: Article

References (13)

1. Chikamatsu K, Mizuno K, Yamada H, Mitarai S. 2009. Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku 84:631-633.
2. Hain Lifescience GmbH. 2009. GenoType MTBDRplus: instruction manual. Hain Lifescience GmbH, Nehren, Germany.
3. Hauck Y, Fabre M, Vergnaud G, Soler C, Pourcel C. 2009. Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J. Antimicrob. Chemother. 64:259-262.
4. Heep M, Rieger U, Beck D, Lehn N. 2000. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:1075-1077. (Pubitemid 30165295)
5. Huang WL, Chen HY, Kuo YM, Jou R. 2009. Performance assessment of the GenoType MTBDRplus test andDNAsequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 47:2520-2524.
6. Jou R, Chen HY, Chiang CY, Yu MC, Su IJ. 2005. Genetic diversity of multidrug-resistant Mycobacterium tuberculosis isolates and identification of 11 novel rpoB alleles in Taiwan. J. Clin. Microbiol. 43:1390-1394. (Pubitemid 40364969)
7. Ling DI, Zwerling AA, Pai M. 2008. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev. Respir. Med. 2:583-588.
8. Luna-Herrera J, Reddy MV, Gangadharam PR. 1995. In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drugresistant (MDR) tubercle bacilli. J. Antimicrob. Chemother. 36:355-363.
9. National Committee for Clinical Laboratory Standards. 2000. Susceptibilty testing of mycobacteria, nocardia, and other aerobic actinomycetes, vol 23, no 18. Approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
10. Senol G, Erbaycu A, Ozsöz A. 2005. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J. Chemother. 17:380-384. (Pubitemid 41284775)
11. Sintchenko V, Chew WK, Jelfs PJ, Gilbert GL. 1999. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology 31:257-260. (Pubitemid 29417609)
12. Uzun M, Erturan Z, Anǧ O. 2002. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int. J. Tuberc. Lung Dis. 6:164-165. (Pubitemid 34263709)
13. Yoshida S, et al. 2010. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J. Infect. Chemother. 16:360-363.